RhumbLine Advisers
FTH

RhumbLine Advisers’s Faeth Therapeutics FTH Stock Holding History

RhumbLine Advisers’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-808
Closed -$37K – 3223
2022
Q1 		$37K Sell
808
-137
-14% -$10.9K ﹤0.01% 2989
2021
Q4 		$110K Buy
945
+116
+14% +$17.3K ﹤0.01% 2931
2021
Q3 		$174K Buy
+829
New +$151K ﹤0.01% 2931

Other funds holding FTH

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RhumbLine Advisers's FTH Position: Q2 2022 in Review

RhumbLine Advisers sold out of Faeth Therapeutics (FTH) in Q2 2022, closing a stake of 808 shares — an estimated $37K sold.

RhumbLine Advisers first reported a position in FTH in Q3 2021 and held it in 3 quarters. The position peaked at $174K in Q3 2021. 39 funds tracked by Wall St. Rank hold FTH as of Q2 2022.

  • RhumbLine Advisers reported no remaining Faeth Therapeutics position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 808 Faeth Therapeutics shares in Q2 2022, an estimated $37K.
  • RhumbLine Advisers first reported a position in Faeth Therapeutics in Q3 2021 and held it in 3 quarters.
  • RhumbLine Advisers's Faeth Therapeutics position peaked at $174K in Q3 2021.
  • 39 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.